Cross-over vaccination
Of the 3,739 women who received HAV at enrollment in CVT, a total of 2,669 were eligible and received crossover HPV2 vaccination. Participants who had received HPV2 vaccine at enrollment in CVT were offered HAV and HBV vaccination.
Long-term follow-up study
The long-term follow-up study includes women from the HPV2 arm, women from the HAV arm who crossed-over to HPV2 and were included in added-value immunogenicity studies (n=556), and women in an unvaccinated cohort enrolled outside the trial setting (n=2,836). All other women in the HAV arm were followed for 2 additional years as part of the long-term follow-up study regardless of their decision about crossover vaccination in order to monitor vaccine safety post-crossover among other outcomes.
Sources of exposed and unexposed pregnancies
We included pregnancies that occurred both in the randomized phase of the CVT and pregnancies in the long-term follow-up study as of a data freeze date of December 2013 (year 4 of the long-term follow-up study). Exposed pregnancies are those in women initially randomized to the HPV2 arm with estimated conception before ("exposed pregnancy set 1") or after (i.e. in the long-term follow-up study) the CVT close-out date ("exposed pregnancy set 2"); as well as pregnancies in women initially randomized to the HAV arm who received crossover HPV2 vaccination in the long-term follow-up but were resolved after HPV2 crossover vaccination ("exposed pregnancy set 3"). The groups of unexposed pregnancies include pregnancies in women in the unvaccinated cohort ("unexposed pregnancy set 1"); pregnancies that occurred in women initially randomized to the HAV arm during the CVT ("unexposed pregnancy set 2"); pregnancies in women initially randomized to HAV but conceived during the long-term followup by women who did not crossover to HPV2 ("unexposed pregnancy set 3"); and pregnancies in women initially randomized to the HAV arm who received crossover HPV2 vaccination but were resolved prior to the crossover vaccination ("unexposed pregnancy set 4").
Statistical analysis
The relative risk (RR) of miscarriage was estimated by fitting a generalized linear model for a binomial distribution with log link.
Pregnancy rates and person-time at risk
Person-time was calculated from the latter of start of the study and sexual debut if after start of the study until the earlier of date of first conception and the end of the study. After a woman had a pregnancy her person time was restarted at the date of the pregnancy outcome.
The person-time at risk for pregnancies conceived any time since HPV2 vaccination was 26,651 person-years during which 3,411 pregnancies were conceived (pregnancy rate, 12.80%).
For unexposed pregnancies, the person-time at risk was 25,029 person-years during which 3,277 pregnancies were conceived (rate, 13.09%).
Pregnancies and miscarriages after the publication of our previous analysis
A total of 5,138 exposed and unexposed pregnancies not included in our previous report occurred in the trial and post-trial phase of CVT. Among the 2,657 pregnancies conceived any time since HPV2 vaccination, 356 ended in miscarriage; when focusing on the risk window of 89 days since HPV2 vaccination, there were 135 pregnancies and 11 miscarriages. The unexposed pregnancies in the same period were 2,481, of which 325 ended in miscarriage.
False-positive report probability (FPRP)
In terms of decision theory, the FPRP justifying a claim of relationship can be seen as the ratio of the expected loss (or cost) from a false positive claim (i.e. claiming an increased miscarriage risk when it does not exist) to the expected loss from a false negative claim (i.e.
claiming no miscarriage risk when the risk does exist). An FPRP setting of 10% is appropriate when the loss from a false positive report is 9-fold higher than the loss from a false negative 
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